MetrioPharm

MetrioPharm AG is a private clinical-stage biotechnology company focused on the treatment of inflammatory and infectious diseases. MetrioPharm aims to modulate immunometabolism with first-in-class self-regulating drug candidates. The company’s platform generates small-molecule metabolic modulators, which have demonstrated preclinical and clinical efficacy across a broad range of inflammatory and infectious diseases, with excellent safety. Based on this core technology, MetrioPharm has created a series of disease-specific drug combinations targeting inflammation, autoimmune, and degenerative diseases. Preclinical and clinical efficacy data have been obtained for multiple sclerosis, arthritis, sepsis, inflammatory bowel disease, and psoriasis.